Among 83 eligible patients ( 41 to CP , 42 to docetaxel ) , the objective response rates were 54 % ( 95 % confidence interval : 39 % -69 % ) and 24 % ( 95 % confidence interval : 11 % -37 % ) and median progression-free survival was 6.6 months and 3.5 months in the CP arm and the docetaxel arm , respectively .